Joseph Tarsia, MD
Neurology · New Orleans, LANPI 1619292356
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $720 of the $1,059 with a category attached, or 67.9%. Alnylam Pharmaceuticals Inc. accounts for 77.1% of it on its own, with 7 other manufacturers making up the rest. 2024 is the largest year on record at $817, 5.9 times the $139 reported in 2019. That places this record below the midpoint for neurology clinicians in LA, where the typical reported total is $2,263.
Across 16 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$817
- Medtronic$66
- Microvention, Inc.$51
- Johnson & Johnson$31
- Biohaven Pharmaceutical Holding Company Ltd.$28
- Portola Pharmaceuticals, LLC$28
- plus $39 from 2 others
Across 231 payments — averaging $5026.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$1.2M
What the payments were for
- Travel & lodging$72068%
- Food & beverage$34032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 6 | $817 |
| Medtronic(3 entities) | 3 | $66 |
| Microvention, Inc. | 2 | $51 |
| Johnson & Johnson | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Portola Pharmaceuticals, LLC | 1 | $28 |
| Imperative Care, Inc | 1 | $21 |
| AbbVie | 1 | $19 |
How this compares
$1,059 in reported general payments places this provider in the 35th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 11 | $949 |
| Cilostazol | 12 | $306 |
| Ezetimibe | 12 | $208 |
| ClopidogrelClopidogrel Bisulfate | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Orleans
- John EnglandNew Orleans$268K
- Brian CopelandNew Orleans$211K
- Bridget BagertNew Orleans$198K
- Sheryl Martin-SchildNew Orleans$106K
- Piotr OlejniczakNew Orleans$82K
- Elizabeth CrabtreeNew Orleans$36K
- Caroline GoldinNew Orleans$36K
- Jesus LoveraNew Orleans$27K
- Julia StaischNew Orleans$22K
- Pooja Mohan RaoNew Orleans$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.